• SPX
  • $5,953.04
  • 0.07 %
  • $4.33
  • DJI
  • $44,144.96
  • 0.63 %
  • $274.60
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,266.48
  • 1.44 %
  • $117.21
  • IXIC
  • $18,931.88
  • -0.21 %
  • -$40.54
Zentalis Pharmaceuticals, Inc. (ZNTL) Stock Price, News & Analysis

Zentalis Pharmaceuticals, Inc. (ZNTL) Stock Price, News & Analysis

Currency in USD Disclaimer

$3.36

$0.18

(5.5%)

Day's range
$3.08
Day's range
$3.38
50-day range
$2.66
Day's range
$5.44
  • Country: US
  • ISIN: US98943L1070
52 wk range
$2.66
Day's range
$18.07
  • CEO: Dr. Kimberly Lynn Blackwell M.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -2.24
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (ZNTL)
  • Company Zentalis Pharmaceuticals, Inc.
  • Price $3.36
  • Changes Percentage (5.5%)
  • Change $0.18
  • Day Low $3.08
  • Day High $3.38
  • Year High $18.07

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/25/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $10.00
  • High Stock Price Target $55.00
  • Low Stock Price Target $4.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$3.26
  • Trailing P/E Ratio -3.26
  • Forward P/E Ratio -3.26
  • P/E Growth -3.26
  • Net Income $-292,191,000

Income Statement

Quarterly

Annual

Latest News of ZNTL

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Zentalis Pharmaceuticals, Inc. Frequently Asked Questions

  • What is the Zentalis Pharmaceuticals, Inc. stock price today?

    Today's price of Zentalis Pharmaceuticals, Inc. is $3.36 — it has increased by +5.5% in the past 24 hours. Watch Zentalis Pharmaceuticals, Inc. stock price performance more closely on the chart.

  • Does Zentalis Pharmaceuticals, Inc. release reports?

    Yes, you can track Zentalis Pharmaceuticals, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Zentalis Pharmaceuticals, Inc. stock forecast?

    Watch the Zentalis Pharmaceuticals, Inc. chart and read a more detailed Zentalis Pharmaceuticals, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Zentalis Pharmaceuticals, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Zentalis Pharmaceuticals, Inc. stock ticker.

  • How to buy Zentalis Pharmaceuticals, Inc. stocks?

    Like other stocks, ZNTL shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Zentalis Pharmaceuticals, Inc.'s EBITDA?

    Zentalis Pharmaceuticals, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Zentalis Pharmaceuticals, Inc.’s financial statements.

  • What is the Zentalis Pharmaceuticals, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Zentalis Pharmaceuticals, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Zentalis Pharmaceuticals, Inc.'s financials relevant news, and technical analysis. Zentalis Pharmaceuticals, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Zentalis Pharmaceuticals, Inc. stock currently indicates a “sell” signal. For more insights, review Zentalis Pharmaceuticals, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.